Author

Fang-Lin Zhang

h-index 16 View on Semantic Scholar

We have 3 of 40 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

VCP‐Regulated LMF2 Stabilizes the Cholesterol Biosynthesis Enzyme HMGCS1 to Drive Cancer Progression and Confer Capecitabine Resistance in Triple‐Negative Breast Cancer

ABSTRACT Triple‐negative breast cancer (TNBC) is the most therapeutically challenging breast cancer subtype owing to its aggressive nature and lack of effective targeted therapies. Here, we identify lipase maturation factor 2 (LMF2), a previously uncharacterized gene in human cancer, as a novel oncogenic driver that pr...

Qian Zhao, Lisa Andriani, Yin-Ling Zhang et al. · Advancement of science · 0 citations

Open access Jul 2026

Enzymatic activity-independent NANS stabilizes LATS2 to drive growth and therapeutic resistance in HR+/HER2- breast cancer

It is discovered that NANS-mediated recruitment of USP7 stabilizes LATS2, driving tumor growth and resistance to endocrine therapy and CDK4/6 inhibitors in breast cancer.

Jia-Yang Cai, Minhua Huang, Shao-You Yang et al. · Nature Communications · 0 citations

Open access Jul 2026

ZNF689 loss impairs homologous recombination sensitizing triple-negative breast cancer to combined PARP and PD-L1 inhibition

A role of ZNF689 is identified in regulation of homologous recombination repair via stabilization of the MRN complex, with ZNF689 deficiency conferring sensitivity to PARP inhibition, which upregulates PD-L1 expression and sensitizes tumors to combination therapy with anti-PD-L1 in TNBC.

Li-Ping Ge, Yu-Ling Xiao, Song-Yang Wu et al. · Nature Communications · 0 citations